[Cutaneous necrosis due to interferon alpha in a patient with melanoma]

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Adjuvant interferon (IFN) therapy is used in melanoma treatment.
• Interferon alpha 2b is a common therapeutic agent.
• Cutaneous necrosis is a known, albeit rare, adverse effect of IFN therapy.

Observation:

• A 55-year-old male patient with retroauricular melanoma received adjuvant interferon alpha 2b therapy.
• The patient developed localized cutaneous necrosis exclusively at one injection site.

Findings:

• The observed cutaneous necrosis was a rare adverse event.
• Necrosis occurred only at a single injection site, suggesting localized reaction.
• This event aligns with previously reported instances of skin necrosis in patients receiving various types of IFN.

Implications:

• This case underscores the importance of monitoring for rare adverse events during adjuvant IFN therapy.
• Understanding localized reactions can inform injection site management and patient counseling.
• Further investigation into the mechanisms of IFN-induced cutaneous necrosis may improve patient safety.